The DOI matches its Crossref record; 63 of the 63 references it cites were found in a registry or an index.
Circulating interleukin‐6 predicts survival in patients with metastatic breast cancer
Open accessAbstract
Interleukin‐6 (IL‐6) is a multifunctional cytokine produced by macrophages, T cells, B cells, endothelial cells and tumour cells. Interleukin‐6 is able to promote tumour growth by upregulating anti‐apoptotic and angiogenic proteins in tumour cells. In murine models it has been demonstrated that antibodies against IL‐6 diminish tumour growth. Several reports have highlighted the prognostic importance of IL‐6 in e.g., prostate and colon cancer. We addressed prospectively the prognostic significance of serum IL‐6 (sIL‐6), measured at diagnosis of metastasis, in 96 unselected and consecutive patients with progressive metastatic breast cancer before the initiation of systemic therapy. The median sIL‐6 value for the breast cancer population was 6.6 ± 2.1 pg/ml. Patients with 2 or more metastatic sites had higher sIL‐6 values compared to those with only 1 metastatic site (respectively 8.15 ± 1.7 pg/ml and 3.06 ± 6.6 pg/ml; p < 0.001). Patients with liver metastasis (8.3 ± 2.4 pg/ml), with pleural effusions (10.65 ± 9.9 pg/ml) and with dominant visceral disease (8.15 ± 3.3 pg/ml) had significantly higher values compared to those without liver metastases (4.5 ± 3.4 pg/ml; p = 0.001), without pleural effusions (5.45 ± 1.5 pg/ml; p = 0.0077) and with dominant bone disease (4.5 ± 1.4 pg/ml; p = 0.007) respectively. No correlation between sIL‐6 and age, menopausal status, performance status, tumour grade, body‐mass index, histology and hormone receptor status was found. Multivariate analysis showed that high levels of serum IL‐6 have independent prognostic value. We conclude that circulating IL‐6 is associated with worse survival in patients with metastatic breast cancer and is correlated with the extent of disease. © 2002 Wiley‐Liss, Inc.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Kishimoto, T. (1989) · Blood · doi:10.1182/blood.v74.1.1.1 · Cited by 2,069
Gabrilovich, D. I., Chen, H. L., Girgis, K. R., Cunningham, H. T., Meny, G. M., Nadaf, S., Kavanaugh, D., & Carbone, D. P. (1996) · Nature Medicine · doi:10.1038/nm1096-1096 · Cited by 1,977
Interleukin-6 family of cytokines and gp130
Kishimoto, T., Akira, S., Narazaki, M., & Taga, T. (1995) · Blood · doi:10.1182/blood.v86.4.1243.bloodjournal8641243 · Cited by 1,272
Interleukin 6 Induces the Expression of Vascular Endothelial Growth Factor
Cohen, T., Nahari, D., Cerem, L. W., Neufeld, G., & Levi, B.-Z. (1996) · Journal of Biological Chemistry · doi:10.1074/jbc.271.2.736 · Cited by 1,039
Menetrier-Caux, C., Montmain, G., Dieu, M. C., Bain, C., Favrot, M. C., Caux, C., & Blay, J. Y. (1998) · Blood · doi:10.1182/blood.v92.12.4778 · Cited by 590
Dankbar, B., Padró, T., Leo, R., Feldmann, B., Kropff, M., Mesters, R. M., Serve, H., Berdel, W. E., & Kienast, J. (2000) · Blood · doi:10.1182/blood.v95.8.2630 · Cited by 566
(1996) · Nature Medicine · doi:10.1038/nm1196-1267 · Cited by 429
Aoki, Y., Jaffe, E. S., Chang, Y., Jones, K., Teruya-Feldstein, J., Moore, P. S., & Tosato, G. (1999) · Blood · doi:10.1182/blood.v93.12.4034 · Cited by 427
Interleukin‐6: Structure‐function relationships
Simpson, R. J., Hammacher, A., Smith, D. K., Matthews, J. M., & Ward, L. D. (1997) · Protein Science · doi:10.1002/pro.5560060501 · Cited by 371
Serum interleukin 6 as a prognostic factor in patients with prostate cancer.
Nakashima, J., Tachibana, M., Horiguchi, Y., Oya, M., Ohigashi, T., Asakura, H., & Murai, M. (2000) · PubMed · Cited by 351
Cited by
Inflammation: The Common Pathway of Stress-Related Diseases
Liu, Y.-Z., Wang, Y.-X., & Jiang, C.-L. (2017) · Frontiers in Human Neuroscience · doi:10.3389/fnhum.2017.00316 · Cited by 800
Interleukin-6 induces an epithelial-mesenchymal transition phenotype in human breast cancer cells
Sullivan, N. J., Sasser, A. K., Axel, A. E., Vesuna, F., Raman, V, Ramirez, N., Oberyszyn, T. M., & Hall, B. M. (2009) · Oncogene · doi:10.1038/onc.2009.180 · Cited by 757
IL-6 and related cytokines as the critical lynchpins between inflammation and cancer
Taniguchi, K., & Karin, M. (2014) · Seminars in Immunology · doi:10.1016/j.smim.2014.01.001 · Cited by 716
Interleukin-6 signaling pathway in targeted therapy for cancer
Guo, Y., Xu, F., Lu, T., Duan, Z., & Zhang, Z. (2012) · Cancer Treatment Reviews · doi:10.1016/j.ctrv.2012.04.007 · Cited by 686
Targeting interleukin-6 in inflammatory autoimmune diseases and cancers
Yao, X., Huang, J., Zhong, H., Shen, N., Faggioni, R., Fung, M., & Yao, Y. (2014) · Pharmacology & Therapeutics · doi:10.1016/j.pharmthera.2013.09.004 · Cited by 664
Inflammation and cancer: interweaving microRNA, free radical, cytokine and p53 pathways
Schetter, A. J., Heegaard, N. H. H., & Harris, C. C. (2010) · Carcinogenesis · doi:10.1093/carcin/bgp272 · Cited by 657
Cytokines and their relationship to the symptoms and outcome of cancer
Seruga, B., Zhang, H., Bernstein, L. J., & Tannock, I. F. (2008) · Nature Reviews Cancer · doi:10.1038/nrc2507 · Cited by 652
Sethi, N., Dai, X., Winter, C. G., & Kang, Y. (2011) · Cancer Cell · doi:10.1016/j.ccr.2010.12.022 · Cited by 577
Korkaya, H., Kim, G.-I., Davis, A., Malik, F., Henry, N. L., Ithimakin, S., Quraishi, A. A., Tawakkol, N., D'Angelo, R., Paulson, A. K., et al. (2012) · Molecular Cell · doi:10.1016/j.molcel.2012.06.014 · Cited by 538
Calder, P. C., Bosco, N., Bourdet-Sicard, R., Capuron, L., Delzenne, N., Doré, J., Franceschi, C., Lehtinen, M. J., Recker, T., Salvioli, S., et al. (2017) · Ageing Research Reviews · doi:10.1016/j.arr.2017.09.001 · Cited by 488
Obesity, adipocytokines, and insulin resistance in breast cancer
Rose, D. P., Komninou, D., & Stephenson, G. D. (2004) · Obesity Reviews · doi:10.1111/j.1467-789x.2004.00142.x · Cited by 460
DNA Damage-Mediated Induction of a Chemoresistant Niche
Gilbert, L. A., & Hemann, M. T. (2010) · Cell · doi:10.1016/j.cell.2010.09.043 · Cited by 428
Significance of interleukin-6 (IL-6) in breast cancer (review)
Knüpfer, H., & Preiß, R. (2007) · Breast Cancer Research and Treatment · doi:10.1007/s10549-006-9328-3 · Cited by 396
Tumor-Associated Macrophages: The Double-Edged Sword in Cancer Progression
Chen, J. J. W., Lin, Y.-C., Yao, P.-L., Yuan, A., Chen, H.-Y., Shun, C.-T., Tsai, M.-F., Chen, C.-H., & Yang, P.-C. (2005) · Journal of Clinical Oncology · doi:10.1200/jco.2005.12.172 · Cited by 374
Cancer prevention and therapy through the modulation of the tumor microenvironment
Casey, S. C., Amedei, A., Aquilano, K., Azmi, A. S., Benencia, F., Bhakta, D., Bilsland, A. E., Boosani, C. S., Chen, S., Ciriolo, M. R., et al. (2015) · Seminars in Cancer Biology · doi:10.1016/j.semcancer.2015.02.007 · Cited by 372
Interleukin‐6 and its receptor in cancer: Implications for Translational Therapeutics
Hong, D. S., Angelo, L. S., & Kurzrock, R. (2007) · Cancer · doi:10.1002/cncr.22999 · Cited by 370
The role of intratumoral and systemic IL-6 in breast cancer
Dethlefsen, C., Højfeldt, G., & Hojman, P. (2013) · Breast Cancer Research and Treatment · doi:10.1007/s10549-013-2488-z · Cited by 363
Jiang, S., Zhang, L., Zhang, H., Hu, S., Lu, M., Liang, S., Li, B., Li, Y., Li, D., Wang, E., et al. (2012) · The EMBO Journal · doi:10.1038/emboj.2012.45 · Cited by 356
Mast cells: the JEKYLL and HYDE of tumor growth
Theoharides, T. C., & Conti, P. (2004) · Trends in Immunology · doi:10.1016/j.it.2004.02.013 · Cited by 351
Interleukin-6, Secreted by Human Ovarian Carcinoma Cells, Is a Potent Proangiogenic Cytokine
Nilsson, M. B., Langley, R. R., & Fidler, I. J. (2005) · Cancer Research · doi:10.1158/0008-5472.can-05-0623 · Cited by 349
IL-6/JAK/STAT3 Signaling in Breast Cancer Metastasis: Biology and Treatment
Manore, S. G., Doheny, D. L., Wong, G. L., & Lo, H.-W. (2022) · Frontiers in Oncology · doi:10.3389/fonc.2022.866014 · Cited by 307
Portrait of inflammatory response to ionizing radiation treatment
Di Maggio, F. M., Minafra, L., Forte, G. I., Cammarata, F. P., Lio, D., Messa, C., Gilardi, M. C., & Bravatà, V. (2015) · Journal of Inflammation · doi:10.1186/s12950-015-0058-3 · Cited by 286
Nicolini, A., Carpi, A., & Rossi, G. (2006) · Cytokine & Growth Factor Reviews · doi:10.1016/j.cytogfr.2006.07.002 · Cited by 279
Lippitz, B. E., & Harris, R. A. (2016) · OncoImmunology · doi:10.1080/2162402x.2015.1093722 · Cited by 248
Hughes, S., Jaremka, L. M., Alfano, C. M., Glaser, R., Povoski, S. P., Lipari, A. M., Agnese, D. M., Farrar, W. B., Yee, L. D., Carson, W. E., et al. (2014) · Psychoneuroendocrinology · doi:10.1016/j.psyneuen.2013.12.016 · Cited by 213
Meneses-Echávez, J. F., Correa-Bautista, J. E., González-Jiménez, E., Schmidt Río-Valle, J., Elkins, M. R., Lobelo, F., & Ramírez-Vélez, R. (2016) · Cancer Epidemiology, Biomarkers & Prevention · doi:10.1158/1055-9965.epi-15-1061 · Cited by 169
Mindfulness and its efficacy for psychological and biological responses in women with breast cancer
Kenne Sarenmalm, E., Mårtensson, L. B., Andersson, B. A., Karlsson, P., & Bergh, I. (2017) · Cancer Medicine · doi:10.1002/cam4.1052 · Cited by 160
Witek Janusek, L., Tell, D., & Mathews, H. L. (2019) · Brain, Behavior, and Immunity · doi:10.1016/j.bbi.2019.04.012 · Cited by 143
Hartman, Z. C., Yang, X.-Y., Glass, O., Lei, G., Osada, T., Dave, S. S., Morse, M. A., Clay, T. M., & Lyerly, H. K. (2011) · Cancer Research · doi:10.1158/0008-5472.can-11-0308 · Cited by 137
Determinants and functions of CAFs secretome during cancer progression and therapy
Linares, J., Marín-Jiménez, J. A., Badia-Ramentol, J., & Calon, A. (2021) · Frontiers in Cell and Developmental Biology · doi:10.3389/fcell.2020.621070 · Cited by 110
Pakiz, B., Flatt, S. W., Bardwell, W. A., Rock, C. L., & Mills, P. J. (2011) · International Journal of Behavioral Medicine · doi:10.1007/s12529-010-9079-8 · Cited by 104
“Even though higher cytokine levels have been associated with increased disease risk across studies, identifying the magnitude of change that could be considered beneficial for health outcomes remains a challenge, possibly as a result of multiple factors effecting this relationship [45, 46].”
BackgroundNon-cell autonomous effects of the senescence-associated secretory phenotype in cancer therapy.
Saleh, T., Tyutynuk-Massey, L., Cudjoe, E. K., Idowu, M. O., Landry, J. W., & Gewirtz, D. A. (2018) · Frontiers in Oncology · doi:10.3389/fonc.2018.00164 · Cited by 85
IL6 Signaling in Peripheral Blood T Cells Predicts Clinical Outcome in Breast Cancer
Wang, L., Miyahira, A. K., Simons, D. L., Lu, X., Chang, A. Y., Wang, C., Suni, M. A., Maino, V. C., Dirbas, F. M., Yim, J., et al. (2017) · Cancer Research · doi:10.1158/0008-5472.can-16-1373 · Cited by 55
An IL-6 link between obesity and cancer
Ghosh, S. (2013) · Frontiers in Bioscience · doi:10.2741/e628 · Cited by 57
Mortalin is a novel mediator of erythropoietin signaling
Ohtsuka, R., Abe, Y., Fujii, T., Yamamoto, M., Nishimura, J., Takayanagi, R., & Muta, K. (2007) · European Journal of Haematology · doi:10.1111/j.1600-0609.2007.00870.x · Cited by 14
Metadata
- Authors
- Salgado, R., Junius, S., Benoy, I., Van Dam, P., Vermeulen, P., Van Marck, E., Huget, P., & Dirix, L. Y.
- Venue
- International Journal of Cancer
- Publisher
- Wiley
- Published
- 2002-11-25
- Volume
- 103
- Issue
- 5
- Pages
- 642-646
- ISSN
- 0020-7136 (ISSN-L)
- 1097-0215
- OpenAlex
- W2028194167
- Cited by
- 435
- References
- 63
- FWCI
- 2.99
- Type
- journal article
- Language
- en
- Open access
- bronze
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.